Review
Copyright ©The Author(s) 2023.
World J Gastroenterol. Jan 21, 2023; 29(3): 413-424
Published online Jan 21, 2023. doi: 10.3748/wjg.v29.i3.413
Table 1 Outcomes of multimodal locoregional therapy for recurrent hepatocellular carcinoma
Ref.
Study design
Treatment
Number of patients
Outcomes
Song et al[95]RetrospectiveRecurrent HCC ≤ 5 cm63 TACE; 96 TACE-RFATACE-RFA lower disease progression than TACE monotherapy; No difference in overall survival
Zhang et al[115]RetrospectiveTreatment Naïve HCC, DEB-TACE-RFA for Recurrent HCC (Group B), and hepatectomy40 DEB-TACE as primary treatment; 36 DEB-TACE Recurrent HCC; 40 hepatectomy as primaryDEB-TACE-RFA can prolong survival time for recurrent HCC
Zheng et al[96]RetrospectiveTACE-RFA or repeat hepatectomy63 TACE-RFA; 38 repeat hepatectomySimilar overall survival for TACE-RFA (38 months) compared to repeat hepatectomy (42 months); No difference in progression free survival
Peng et al[94]RetrospectiveRecurrent HCC ≤ 5 cmTACE-RFA or repeat hepatectomy107 TACE-RFA; 79 repeat hepatectomyNo difference in overall survival or disease-free survival; TACE-RFA has lower complications and shorter hospital stays
Ji et al[98]RetrospectiveRecurrent HCC with three or fewer tumors < 3 cm17 TACE-MWA; 28 TACETACE-MWA showed better 1-,3-, 6- month tumor response; TACE-MWA showed prolonged 1-,3-, 5-year progression free survival; No difference in overall survival
Table 2 Locoregional therapy and oral agents for recurrent hepatocellular carcinoma
Ref.
Study Design
Treatment
Number of Patients
Outcomes
Wan et al[105]RetrospectiveRecurrent HCC ≤ 5 cm127 TACE; 127 Sorafenib + TACESorafenib + TACE increased survival time compared to TACE alone (30.7 vs 18.22 mo); Longer duration of Sorafenib when treated with Sorafenib + TACE associated with survival
Peng et al[106]RetrospectiveRecurrent HCC ≤ 7 or five nodules ≤ 3 cm106 TACE-RFA + Sorafenib; 101 SorafenibLonger median overall survival and time to progression for combination therapy
Guo et al[109]RetrospectiveRecurrent HCC20 TACE+ camrelizumab; 51 TACENo difference in tumor response, progression-free survival, or overall survival